Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decanoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.71 |
| ▸ | PPARG | P37231 | 7/20 | 0.71 |
| ▸ | PPARD | Q03181 | 7/20 | 0.71 |
| ▸ | PPARA | Q07869 | 7/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.71 |
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.71 |
| ▸ | FABP4 | P15090 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | TLR2 | O60603 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.71 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stearic Acid SCHEMBL8658083 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL16736954 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL709152 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL6721200 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL17075370 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Tridecanoate SCHEMBL16266603 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL17075372 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL7858318 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Behenic Acid SCHEMBL22687520 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL1244008 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | claimed |
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | claimed |
| US-20250332120-A1 | COMPOSITION FOR EXTERNAL PREPARATION | KAO CORPORATION (JP) | 2025-10-30 | — | — | US | claimed |
| CN-117224420-B | Oil-soluble lip-rounding compound peptide and preparation method thereof | 南京斯拜科生物科技股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | claimed |
| CN-117771176-A | Self-microemulsion composition of lenatinib, drug delivery system and solid preparation | 湖南慧泽生物医药科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20240050371-A1 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | US | claimed |
| US-11826467-B2 | W/O/W microemulsions for ocular administration | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-11-28 | — | — | US | claimed |
| CN-116327759-A | Composition containing butylphthalide, edaravone and borneol and compound soft capsule | 千乘镜像(北京)科技有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-115955959-A | Nanostructured lipid carrier delivery systems, compositions, and methods | 康普萨姆公司 | 2023-04-11 | — | — | CN | claimed |
| EP-2561865-A2 | TRANSDERMAL ABSORPTION PREPARATION | Icure Pharmaceutical Inc. (KR) | 2013-02-27 | — | — | EP | claimed |
| CN-101437394-B | Cationic antiseptic compositions and methods of use | 3M INNOVATIVE PROPERTIES CO | 2012-10-10 | — | — | CN | claimed |
| CN-101437394-A | Cationic antiseptic compositions and methods of use | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-20 | — | — | CN | claimed |
| CN-101170985-A | Hardenable antimicrobial dental compositions and methods | 3M INNOVATIVE PROPERTIES CO (US) | 2008-04-30 | — | — | CN | claimed |
| CN-101048064-A | Antimicrobial compositions and methods of use | 3M INNOVATIVE PROPERTIES CO (US) | 2007-10-03 | — | — | CN | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | claimed |
| EP-1117380-A1 | GLUCOSIDE PAUCILAMELLAR VESICLES | Igen, Inc. (US) | 2001-07-25 | — | — | EP | claimed |
| US-6251425-B1 | Glucoside paucilamellar vesicles | IGEN, INC. | 2001-06-26 | — | — | US | claimed |
| WO-2000019980-A1 | GLUCOSIDE PAUCILAMELLAR VESICLES | IGEN, INC. (US) | 2000-04-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539313-B2 | Microbial removal | CUTA, MIF, PCNA | GPR84 2136/4885PPARG 527/4885PPARD 190/4885 |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | GPR84 2684/4885PPARG 1982/4885PPARD 1929/4885 |
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | GPR84 1329/4885PPARG 9/4885PPARD 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.